Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
US10583129B2 · kind B2 · utility
2Cited by
9References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 21, 2019 |
| Grant date | Mar 10, 2020 |
| Priority date | — |
| Expiry date | May 21, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention is directed to prostaglandin E2 receptor 4 (EP4) antagonists useful in the treatment of nonalcoholic steatohepatitis (NASH)-associated liver cancer in a human or animal. The method comprises administering one or more of Compound A, Compound B or Compound C, or pharmaceutically acceptable salts thereof, as the EP4 antagonist(s). The method may include a pharmaceutical composition comprising the EP4 antagonist, and may include one or more other active agents and/or therapies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.